MEDIROM MOTHER Labs Inc. Secures ¥9 Billion Valuation in Series A Round with Investment from Internal Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2025
0mins
Should l Buy MRM?
Source: Newsfilter
Private Placement Announcement: MEDIROM MOTHER Labs Inc. has approved a private placement of new shares to its President and CEO, Yoshio Uekusa, and Director, Ryo Saito, as part of its Series A financing round, valuing the company at JPY9 billion, with funding expected by the end of October.
Business Expansion Goals: The capital increase aims to strengthen MOTHER Labs' management structure and decision-making, facilitating the development of an upgraded wearable device, the MOTHER Bracelet, and enhancing product market entry strategies to drive growth in the healthcare and wellness sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRM
About MRM
Medirom Healthcare Technologies Inc is a Japan-based holistic health services provider. The Company is a franchiser and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers and government entities. The Company mainly operates in two business segments. The Relaxation Salon Segment is engaged in the development of relaxation studios nationwide, centered on Re.Ra.Ku for the purpose of health management services. The Digital Preventative Healthcare Segment is involved in the sampling business, which includes brand promotion and consumer analysis for third party brands of corporate clients, government-sponsored specific health guidance program, utilizing internally-developed on-demand health monitoring smartphone application Lav, as well as MOTHER Tracker for fitness applications, and preventative healthcare services utilizing digital application and devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Micromem Technologies Closes C$327,778 Private Placement
- Successful Private Placement: Micromem Technologies has closed a non-brokered private placement, raising approximately C$327,778 by issuing 6,555,555 units at C$0.05 each, indicating market confidence in its financing needs.
- Clear Use of Proceeds: The funds raised will be allocated for working capital, reflecting Micromem's strategic intent to enhance its intelligent application development capabilities, particularly in sectors like oil & gas and healthcare.
- Compliance Requirements: The securities issued are subject to post-closing compliance requirements from the Canadian Securities Exchange, ensuring the company operates within legal frameworks and bolstering investor confidence.
- Future Financing Potential: Micromem may close an additional tranche of up to C$167,000 as needed, demonstrating the company's proactive planning for future capital requirements to further support its business growth.
See More
MRM Health Receives FDA Clearance to Initiate MH002 Clinical Trial
- Clinical Trial Launch: MRM Health's MH002 program has received FDA clearance, marking the initiation of the STARFISH-UC Phase 2b clinical trial, which is expected to enroll approximately 204 patients with mild-to-moderate ulcerative colitis, advancing the development of next-generation therapies for inflammatory bowel diseases.
- Efficacy Validation: MH002 demonstrated excellent safety and encouraging efficacy in its Phase 2a trial, with significant mucosal healing and anti-inflammatory effects observed after 8 weeks of treatment, laying a solid foundation for the upcoming Phase 2b trial.
- Innovative Technology Platform: MH002 is designed and manufactured using MRM Health's CORAL® platform, ensuring drug consistency and high quality, which supports cost-effective treatments for chronic inflammatory conditions and holds significant market potential.
- Funding Support: MRM Health successfully closed a €55 million Series B round in September 2025, enhancing its R&D capabilities in inflammatory diseases and providing financial backing for future clinical advancements.
See More
MEDIROM Surpasses 20,000 Human Authentications with 'Orb' Device
- Surge in Authentications: As of December 28, 2025, MEDIROM has surpassed 20,000 human authentications using the 'Orb' device at its subsidiary's 'Re.Ra.Ku' relaxation salons, doubling from 10,000 cases on October 23, 2025, indicating rapid growth potential in digital infrastructure.
- Event-Driven Growth: The spike in authentications was largely driven by the company's 25th anniversary event, ‘The 5-Minute Shoulder Massage Campaign for 250,000 People,’ which attracted significant customer interest by offering free shoulder massages, facilitating rapid technology adoption.
- Nationwide Expansion Plans: MEDIROM aims to install 'Orb' devices in 200 salons across the country, progressively broadening access to this new social infrastructure, thereby enhancing customer experience and competitive positioning in the market.
- Strategic Partnership Outlook: MEDIROM's involvement in the 'World' project, aimed at creating the largest network of real humans, positions the company favorably for future developments in digital infrastructure, driving ongoing growth in the health tech sector.
See More
MEDIROM Partners with Tools for Humanity to Launch Proof of Human Technology in Japan
- Agreement Signed: MEDIROM has entered into a Master Service Agreement with Tools for Humanity and World Foundation to operate Proof of Human verification locations in Japan, which is expected to gradually increase revenue through operational fees and related services, driving the company's transformation in the health tech sector.
- Technology Deployment Plan: MEDIROM will introduce advanced privacy-preserving technology, “Orbs,” in approximately 300 Re.Ra.Ku locations, enhancing the credibility of human verification while boosting customer trust in the digital society, thereby promoting diversified business development.
- Task Force Establishment: To support the nationwide rollout of Proof of Human technology, MEDIROM has established the “MEDIROM World Proof of Human Task Force,” which will strengthen its organizational structure to ensure rapid deployment and effective operation of the technology, further solidifying its leadership in the health tech field.
- Social Impact Enhancement: This collaboration not only opens new revenue models for MEDIROM but also contributes to building trust within Japan's digital society, aligning with the global demand for human identity verification and showcasing the company's foresight in technological innovation and social responsibility.
See More
MEDIROM Partners with Tools for Humanity to Launch Proof of Human Technology in Japan
- Master Service Agreement Signed: MEDIROM has entered into a Master Service Agreement with Tools for Humanity and World Foundation to operate Proof of Human verification locations in Japan, which is expected to gradually enhance the company's revenue through operational fees and related services.
- Technology Deployment Plan: MEDIROM will introduce advanced privacy-preserving Orbs in approximately 300 Re.Ra.Ku locations, enabling rapid and trusted human verification, thereby enhancing customer trust and expanding market reach.
- Organizational Structure Optimization: To support the nationwide rollout of Proof of Human technology, MEDIROM has established a dedicated “Proof of Human Task Force,” strengthening its organizational structure to adapt to the new business model and drive its transformation into a health tech company.
- Social Impact Outlook: Through collaboration with Tools for Humanity, MEDIROM aims to establish a trusted digital society infrastructure that encourages participation in the digital society, further elevating the company's position in the health tech industry.
See More
MEDIROM Partners with Tools for Humanity to Launch Proof of Human Technology in Japan
- Agreement Signed: MEDIROM has entered into a Master Service Agreement with Tools for Humanity and World Foundation to operate Proof of Human verification locations in Japan, which is expected to generate long-term revenue through operational fees and related services.
- Technology Deployment Plan: MEDIROM will introduce advanced privacy-preserving technology, Orbs, in approximately 300 Re.Ra.Ku locations to verify human identity, thereby enhancing customer trust and encouraging participation in the digital society.
- Organizational Structure Optimization: To support the nationwide rollout of Proof of Human technology, MEDIROM has established a dedicated
See More
Micromem Technologies Closes C$327,778 Private Placement
- Successful Private Placement: Micromem Technologies has closed a non-brokered private placement, raising approximately C$327,778 by issuing 6,555,555 units at C$0.05 each, indicating market confidence in its financing needs.
- Clear Use of Proceeds: The funds raised will be allocated for working capital, reflecting Micromem's strategic intent to enhance its intelligent application development capabilities, particularly in sectors like oil & gas and healthcare.
- Compliance Requirements: The securities issued are subject to post-closing compliance requirements from the Canadian Securities Exchange, ensuring the company operates within legal frameworks and bolstering investor confidence.
- Future Financing Potential: Micromem may close an additional tranche of up to C$167,000 as needed, demonstrating the company's proactive planning for future capital requirements to further support its business growth.
See More
MRM Health Receives FDA Clearance to Initiate MH002 Clinical Trial
- Clinical Trial Launch: MRM Health's MH002 program has received FDA clearance, marking the initiation of the STARFISH-UC Phase 2b clinical trial, which is expected to enroll approximately 204 patients with mild-to-moderate ulcerative colitis, advancing the development of next-generation therapies for inflammatory bowel diseases.
- Efficacy Validation: MH002 demonstrated excellent safety and encouraging efficacy in its Phase 2a trial, with significant mucosal healing and anti-inflammatory effects observed after 8 weeks of treatment, laying a solid foundation for the upcoming Phase 2b trial.
- Innovative Technology Platform: MH002 is designed and manufactured using MRM Health's CORAL® platform, ensuring drug consistency and high quality, which supports cost-effective treatments for chronic inflammatory conditions and holds significant market potential.
- Funding Support: MRM Health successfully closed a €55 million Series B round in September 2025, enhancing its R&D capabilities in inflammatory diseases and providing financial backing for future clinical advancements.
See More
MEDIROM Surpasses 20,000 Human Authentications with 'Orb' Device
- Surge in Authentications: As of December 28, 2025, MEDIROM has surpassed 20,000 human authentications using the 'Orb' device at its subsidiary's 'Re.Ra.Ku' relaxation salons, doubling from 10,000 cases on October 23, 2025, indicating rapid growth potential in digital infrastructure.
- Event-Driven Growth: The spike in authentications was largely driven by the company's 25th anniversary event, ‘The 5-Minute Shoulder Massage Campaign for 250,000 People,’ which attracted significant customer interest by offering free shoulder massages, facilitating rapid technology adoption.
- Nationwide Expansion Plans: MEDIROM aims to install 'Orb' devices in 200 salons across the country, progressively broadening access to this new social infrastructure, thereby enhancing customer experience and competitive positioning in the market.
- Strategic Partnership Outlook: MEDIROM's involvement in the 'World' project, aimed at creating the largest network of real humans, positions the company favorably for future developments in digital infrastructure, driving ongoing growth in the health tech sector.
See More
MEDIROM Partners with Tools for Humanity to Launch Proof of Human Technology in Japan
- Agreement Signed: MEDIROM has entered into a Master Service Agreement with Tools for Humanity and World Foundation to operate Proof of Human verification locations in Japan, which is expected to gradually increase revenue through operational fees and related services, driving the company's transformation in the health tech sector.
- Technology Deployment Plan: MEDIROM will introduce advanced privacy-preserving technology, “Orbs,” in approximately 300 Re.Ra.Ku locations, enhancing the credibility of human verification while boosting customer trust in the digital society, thereby promoting diversified business development.
- Task Force Establishment: To support the nationwide rollout of Proof of Human technology, MEDIROM has established the “MEDIROM World Proof of Human Task Force,” which will strengthen its organizational structure to ensure rapid deployment and effective operation of the technology, further solidifying its leadership in the health tech field.
- Social Impact Enhancement: This collaboration not only opens new revenue models for MEDIROM but also contributes to building trust within Japan's digital society, aligning with the global demand for human identity verification and showcasing the company's foresight in technological innovation and social responsibility.
See More
MEDIROM Partners with Tools for Humanity to Launch Proof of Human Technology in Japan
- Master Service Agreement Signed: MEDIROM has entered into a Master Service Agreement with Tools for Humanity and World Foundation to operate Proof of Human verification locations in Japan, which is expected to gradually enhance the company's revenue through operational fees and related services.
- Technology Deployment Plan: MEDIROM will introduce advanced privacy-preserving Orbs in approximately 300 Re.Ra.Ku locations, enabling rapid and trusted human verification, thereby enhancing customer trust and expanding market reach.
- Organizational Structure Optimization: To support the nationwide rollout of Proof of Human technology, MEDIROM has established a dedicated “Proof of Human Task Force,” strengthening its organizational structure to adapt to the new business model and drive its transformation into a health tech company.
- Social Impact Outlook: Through collaboration with Tools for Humanity, MEDIROM aims to establish a trusted digital society infrastructure that encourages participation in the digital society, further elevating the company's position in the health tech industry.
See More
MEDIROM Partners with Tools for Humanity to Launch Proof of Human Technology in Japan
- Agreement Signed: MEDIROM has entered into a Master Service Agreement with Tools for Humanity and World Foundation to operate Proof of Human verification locations in Japan, which is expected to generate long-term revenue through operational fees and related services.
- Technology Deployment Plan: MEDIROM will introduce advanced privacy-preserving technology, Orbs, in approximately 300 Re.Ra.Ku locations to verify human identity, thereby enhancing customer trust and encouraging participation in the digital society.
- Organizational Structure Optimization: To support the nationwide rollout of Proof of Human technology, MEDIROM has established a dedicated
See More
